Clinical Trial Search

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Percentage Decrease in Migraine Episodes — 48; 57; 46 Percentage decrease in migraine episodes — p=0.6207

Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper — -3.8; -3.6; -3.8; -3.3 Migraine…

Primary: Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine. — 5.35; 5.31; 0.77; 0.93 Migraine days by…

Primary: Incidence Rate of Dysphagia — 0.4 events per 1,000 person-months

Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks

Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants

Primary: Headache Days — 23.64; 24.33 Days — p=0.83

Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale

Primary: Headache Days — 5.1; 5.2 Headache days per 4 weeks

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Pain Relief (PR) — 105; 21; 88; 72 Attacks — p=<0.001

Primary: Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. — -5.67; -3.5 days — p=0.4267

Primary: Change From Baseline in Mean Migraine Headache Rates During the Entire 14-week Maintenance Period — -1.4; -1.4; -1.6 Number of migraine headaches

Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days — 40.0; 12.0 percentage of participants — p=<0.001

Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01

Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Change in Frequency of Migraine Days During the Last 28 Day Interval of the Treatment Period as Compared to the 28 Day Baseline Period. — 4.5 days

Primary: Absolute Change From Baseline in the Frequency of Migraine Attacks — -0.8; -1.0; -1.0 number of migraine attacks/participant

Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days

Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -1.86; -4.29 migraine days per month — p=<0.0001

Primary: 30 Minute Pain Score — 3; 3; 3 score on a scale

Primary: Headache Pain Relief at 2 hr — 40; 62; 58; 68 Participants — p=0.0012

Primary: Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of…

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration — -1.5; -1.3 Migraine days/four weeks…

Primary: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 — 232; 35…